• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Biomarin Pharmaceutical

Biomarin Pharmaceutical

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Research and Markets: Hemophilia A Pipeline Review, H1 2015 - 32 Companies & 39 Drug Profiles

    Research and Markets: Hemophilia A Pipeline Review, H1 2015 - 32 Companies & 39 Drug Profiles

  2. UPDATE: The U.S. markets have reached a major bull-bear test

    UPDATE: The U.S. markets have reached a major bull-bear test

  3. UPDATE: The U.S. markets have reached a major -2-

    UPDATE: The U.S. markets have reached a major -2-

  4. The U.S. markets have reached a major bull-bear test

    The U.S. markets have reached a major bull-bear test

  5. The U.S. markets have reached a major -2-

    The U.S. markets have reached a major -2-

  6. Research and Markets: Endometrial Cancer Therapeutics Pipeline Review, H1 2015 - 35 Companies & 48 Drug Profiles

    Research and Markets: Endometrial Cancer Therapeutics Pipeline Review, H1 2015 - 35 Companies & 48 Drug Profiles

  7. CureDuchenne Cares Launches Website to Share Valuable Resources with the Duchenne Community

    CureDuchenne Cares Launches Website to Share Valuable Resources with the Duchenne Community

  8. Investing in Hidden Assets

    Use this screen to find high-growth businesses that have big ideas to keep competitors at bay.

  9. A Young Power Couple's Kickstart Portfolio

    With "massive" student debt loads receding in the rearview mirror, a young professional couple fires up their investment plan.

  10. Our Outlook for Health-Care Stocks

    Health-care stocks are on a tear as demand slowly returns.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.